96 related articles for article (PubMed ID: 17565147)
1. Researchers wonder why high-risk women are not taking chemoprevention drugs.
Savage L
J Natl Cancer Inst; 2007 Jun; 99(12):913-4. PubMed ID: 17565147
[No Abstract] [Full Text] [Related]
2. Independent assessment supports a role for tamoxifen in breast cancer risk reduction.
Oncology (Williston Park); 1999 Sep; 13(9):1211. PubMed ID: 10509317
[No Abstract] [Full Text] [Related]
3. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
McKay A; Latosinsky S; Martin W
Cancer; 2005 Jan; 103(1):209-10. PubMed ID: 15540238
[No Abstract] [Full Text] [Related]
4. Tamoxifen. To take or not to take. That is the question.
Blanchard P
Tex Nurs; 1999 Aug; 73(7):4-5, 7. PubMed ID: 11949057
[No Abstract] [Full Text] [Related]
5. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Kondo M; Hoshi SL; Toi M
Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
[TBL] [Abstract][Full Text] [Related]
6. Why is breast cancer chemoprevention such a hard sell?
Peres J
J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24815870
[No Abstract] [Full Text] [Related]
7. Venous thromboembolic disease and stroke in women taking tamoxifen for breast cancer chemoprevention.
Isaacs C
Clin Adv Hematol Oncol; 2005 Dec; 3(12):913-4. PubMed ID: 16555431
[No Abstract] [Full Text] [Related]
8. Chemoprevention of breast cancer.
Castrellon AB; Glück S
Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention in postmenopausal women.
Rastogi P
Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
[TBL] [Abstract][Full Text] [Related]
10. Seven for 2007: seven things you should know about breast cancer risk. There's no big way to reduce your risk for breast cancer, but a combination of approaches could make a difference.
Harv Womens Health Watch; 2007 Jan; 14(5):1-3. PubMed ID: 17304697
[No Abstract] [Full Text] [Related]
11. Tamoxifen reduces breast cancer rate in at-risk healthy women by nearly a third, finds study.
Kmietowicz Z
BMJ; 2014 Dec; 349():g7596. PubMed ID: 25500812
[No Abstract] [Full Text] [Related]
12. ACP Journal Club. Tamoxifen for 5 years reduced 16-year risk for breast cancer in women at increased risk.
Parsons H; Stearns V
Ann Intern Med; 2015 May; 162(10):JC11. PubMed ID: 25984872
[No Abstract] [Full Text] [Related]
13. Breast cancer: tamoxifen - offering a long-term prevention option.
Errico A
Nat Rev Clin Oncol; 2015 Feb; 12(2):66. PubMed ID: 25583681
[No Abstract] [Full Text] [Related]
14. IBIS-I tamoxifen update: maturity brings questions.
Chlebowski RT
Lancet Oncol; 2015 Jan; 16(1):7-9. PubMed ID: 25497695
[No Abstract] [Full Text] [Related]
15. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
Jordan VC
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
[No Abstract] [Full Text] [Related]
17. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
18. Alternate dosing schedules for cancer chemopreventive agents.
Lazzeroni M; DeCensi A
Semin Oncol; 2016 Feb; 43(1):116-122. PubMed ID: 26970130
[TBL] [Abstract][Full Text] [Related]
19. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients.
Ma AM; Barone J; Wallis AE; Wu NJ; Garcia LB; Estabrook A; Rosenbaum-Smith SM; Tartter PI
Am J Surg; 2008 Oct; 196(4):500-4. PubMed ID: 18809051
[TBL] [Abstract][Full Text] [Related]
20. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
